

Listing of the Claims:

1. (Cancelled)
2. (Currently Amended) ~~Use according to claim 1-~~ The method of claim 11 wherein the newborn subject is a mammal in the first four weeks after birth.
3. (Currently Amended) ~~Use according to claim 1-~~ The method of claim 11 wherein the newborn or fetal subject is a human.
4. (Cancelled)
5. (Currently Amended) ~~Use according to claim 1-~~ The method of claim 11 wherein the xenon is administered in combination with a sedative, an anaesthetic agent or a further analgesic agent.
6. (Currently Amended) ~~Use according to claim 1-~~ The method of claim 11 wherein the medicament is in gaseous form.
7. (Cancelled)
8. (Currently Amended) ~~Use according to claim 1-~~ The method of claim 11 wherein the medicament is in liquid form.
9. (Cancelled)
10. (Cancelled)
11. (Currently Amended) A method of providing analgesia in a newborn subject, the method comprising administering to ~~the subject~~ a newborn subject in need of analgesia a therapeutically effective amount of xenon.

12. (Currently Amended) A method of providing analgesia in a fetal subject, the method comprising administering to the mother of the fetal subject, the fetal subject in need of analgesia, a therapeutically effective amount of xenon ~~for both the mother and~~ the fetal subject.
13. (Previously Presented) A method accordingly to claim 11 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.
14. (Previously Presented) A method according to claim 11 wherein the xenon is administered in the form of a 20 to 70% v/v xenon/air mixture.
15. (Previously Presented) A method according to claim 11 wherein the xenon is administered in the form of a lipid emulsion.
16. (Previously Presented) A method according to claim 11 wherein the xenon is administered intravenously, neuraxially or transdermally.
17. (Previously Presented) A method accordingly to claim 12 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.
18. (Previously Presented) A method according to claim 12 wherein the xenon is administered in the form of a 20 to 70% v/v xenon/air mixture.
19. (Previously Presented) A method according to claim 12 wherein the xenon is administered in the form of a lipid emulsion.
20. (Previously Presented) A method according to claim 12 wherein the xenon is administered intravenously, neuraxially or transdermally.
21. (New) The method according to claim 12, wherein the xenon is administered to the mother prior to labor.

22. (New) The method according to claim 12, wherein the xenon is administered to the mother during labor.
23. (New) The method of claim 5, wherein the further analgesic agent is an alpha-2-adrenergic agonist, an opiate, or a non-steroidal anti-inflammatory drug.
24. (New) The method of claim 5, wherein the sedative or anaesthetic agent promotes GABAergic activity.